Stockhead’s Sarah Hughan sits down with Aroa Biosurgery (ASX:ARX) founder and CEO Dr Brian Ward to get the short end of the long story on the company’s latest news.

The soft tissue repair products company has released its half yearly report for H1 FY25.

With a cash balance of  NZ$21.6m at the end of September, Aroa is moving in the right direction towards positive cashflow.

Tune in to hear Aroa Biosurgery’s Dr Brian Ward on the financial highlights, the H2 FY25 forecast and more.

 

This video was developed in collaboration with Aroa Biosurgery, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Read MoreHealth

Featured Companies

You might be interested in